Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences Inc. has a significant shareholder disclosure from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation. As of June 30, 2026, these entities report beneficial ownership of 958,520 shares of USANA common stock, par value $0.001 per share.
This position represents 5.19% of the outstanding common stock. Renaissance reports sole voting power and sole dispositive power over all 958,520 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.
USANA Health Sciences reported weaker results for the quarter ended July 4, 2026. Net sales were $223.3 million, down from $235.8 million, as Core Nutritional and Hiya both declined, partly offset by strong growth at Rise. Core Nutritional still represented about 84% of year-to-date sales, with approximately 384,000 active customers, down 8.1% year over year.
The company posted a net loss attributable to USANA of $21.4 million versus prior-year earnings of $9.7 million, or $(1.16) per diluted share compared with $0.52. Results were heavily affected by a non-cash goodwill impairment charge of $29.1 million in the Hiya reporting unit following lower-than-expected performance and reduced forecasts. Despite the loss, operating cash flow for the first six months was $33.1 million and cash and cash equivalents were $168.6 million, with no borrowings outstanding on the $75 million credit facility.
USANA Health Sciences reported fiscal Q2 2026 net sales of $223 million, down 5% year over year, and a net loss attributable to USANA of $(21.4) million versus prior-year net earnings of $9.7 million. Diluted EPS was $(1.16), including an estimated preliminary non-cash goodwill impairment charge of $29.1 million related to the Hiya reporting unit. Adjusted diluted EPS was $(0.07) compared with $0.74, and Adjusted EBITDA attributable to USANA was $27.8 million, down 9%.
The Core Nutritional segment generated net sales of $192 million, down 4%, with active customers declining 8% to 384,000. Hiya net sales were $28 million with active monthly subscribers down 17% to 166,000, while Rise Wellness delivered $3 million of net sales, up 40% year over year but sharply lower sequentially due to a packaging-related disruption.
Management reduced its fiscal 2026 outlook, now expecting consolidated net sales of $910 million, a net loss of $(11) million, adjusted diluted EPS of $0.76 and Adjusted EBITDA of $87 million, all below prior guidance ranges. The company ended Q2 with $169 million in cash and cash equivalents, no debt, and generated $20 million of free cash flow.
USANA Health Sciences chief information officer Peter Benedict reported equity compensation activity on July 25, 2026. A derivative transaction converted 598 restricted stock units into 598 shares of common stock, and a related Form F transaction withheld 176 common shares at $21.32 per share as payment of exercise price or tax liability. Following the derivative transaction, 38,004 restricted stock units remain outstanding, and each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong reported the vesting and settlement of 1,166 Restricted Stock Units into the same number of common shares on July 25, 2026. In a related transaction, 518 common shares were withheld, reported as payment of exercise price or tax liability at $21.32 per share. Following the RSU conversion, Armstrong directly held 39,426 Restricted Stock Units.
On July 23, 2026, USANA Health Sciences director Timothy E. Wood exercised 1,632 Restricted Stock Units, receiving the same number of common shares. In a related step, 408 shares were withheld to pay the exercise price or tax liability at $20.92 per share. After this conversion, he holds 4,895 Restricted Stock Units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Frederic J. Winssinger, a director of USANA Health Sciences, exercised restricted stock units covering 1,632 shares of common stock on July 23, 2026. The conversion transferred RSUs into shares with no reported market sale, resulting in 9,733 common shares held directly and 4,895 restricted stock units remaining outstanding.
USANA Health Sciences Inc. director J. Scott Nixon reported an equity compensation event on July 23, 2026. He exercised 1,632 Restricted Stock Units, receiving 1,632 shares of common stock. Following this conversion, he directly holds 11,445 common shares and 4,895 Restricted Stock Units.
USANA Health Sciences director Gilbert A. Fuller reported the vesting and conversion of 1,632 Restricted Stock Units into 1,632 shares of common stock on July 23, 2026. After this equity award conversion, he holds 1,632 common shares and 4,895 Restricted Stock Units. Each unit represents a contingent right to one share and vests 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.
Peggie Pelosi, a director of USANA Health Sciences, exercised 1,632 restricted stock units into an equal number of common shares on July 23, 2026. 935 shares of common stock were withheld at $20.92 per share to cover tax obligations. Following these transactions she directly holds 4,895 restricted stock units, which vest 25% on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027.